Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012818 · ClinicalTrials.gov registry record · NA
Efficacy and Cost Effectiveness of Relaxation and Response to CHF
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT00012818: Completed NA study, sponsored by US Department of Veterans Affairs.
NCT00012818 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012818, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
Despite the development of significant pharmaceutical treatments, morbidity and mortality of chronic heart failure (CHF) patients remain high, patients� quality of life is poor, and their health care utilization is heavy. It is therefore important to find a cost effective non-pharmaceutical treatment to help CHF patients manage the disease. The relaxation response has been found to be effective in managing CHF-related conditions. With its favorable physiological changes, the relaxation response is likely to benefit CHF patients.
Interventions
- BEHAVIORAL relaxation technique
- BEHAVIORAL educational program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Est. Completion | 2003-09 |
| Phase | NA |
What the finished NCT00012818 record still lists
NCT00012818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which relaxation technique is the first listed.
NCT00012818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00012818 about?
NCT00012818 is a clinical study titled "Efficacy and Cost Effectiveness of Relaxation and Response to CHF". Despite the development of significant pharmaceutical treatments, morbidity and mortality of chronic heart failure (CHF) patients remain high, patients� quality of life is poor, and their health care utilization is heavy. It is therefore important to find a cost effective non-pharmaceutical treatmen...
What is the current status of trial NCT00012818?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00012818?
The interventions under investigation include: relaxation technique (BEHAVIORAL), educational program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00012818?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00012818's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery